|
COX-2 inhibitors
| | | | |
|
Müller et al. 2006 [238]
|
RCT
|
Celecoxib (200 mg bid) + reboxetine versus placebo + reboxetine
|
40 MDD (acute)
|
Significantly greater decrease in depressive symptoms in the treatment group (P = 0.035)
|
|
Akhondzadeh et al. 2009 [239]
|
RCT
|
Celecoxib (200 mg bid) + fluoxetine versus placebo + fluoxetine
|
40 MDD
|
Significant improvement of depressive symptoms (P <0.001), and a greater percentage of responders (90% versus 50%, P = 0.01) and remission (35% versus 5%, P = 0.04) in the treatment group
|
|
Medlewicz et al. 2006 [240]
|
Open-label
|
Acetylsalicylic acid (160 mg qd) + SRI
|
24 MDD and BPD
|
52.4% responder rate, significant improvement within one week (P <0.0001) following treatment; sustained at four weeks
|
|
ClinicalTrials.gov http://www.clinicaltrials.gov/NCT00510822 completed, pending results
|
RCT
|
Cimicoxib (50 mg bid) + sertraline versus placebo + sertraline
|
169 MDD
|
Primary outcome measure is mean change in Hamilton Depression Rating Scale from baselineto six-week endpoint
|
|
Nery et al. 2008 [263]
|
RCT
|
Celecoxib versus placebo
|
28 BPD (depressive and mixed states)
|
No significant differences in depressive or manic symptoms.
|
|
Müller et al. 2002 [242]
|
RCT
|
Celecoxib (400 mg qd) + risperidone versus placebo + risperidone
|
50 (acute schizophrenia)
|
Significant improvement of positive and negative symptoms (P = 0.05), as well as cognition (P <0.06) in treatment group at five weeks
|
|
Müller et al. 2010 [244]
|
RCT
|
Celecoxib + amisulpride versus placebo + amisulpride
|
49 schizophrenia (first-episode)
|
Significant improvement of positive and negative symptoms in celecoxib plus amisulpride group relative to amisulpride alone (P <0.001) at six-weeks
|
|
Sayyah et al. 2011 [245]
|
RCT
|
Celecoxib (200 mg bid) + fluoxetine versus placebo + fluoxetine
|
50 OCD
|
Significantly greater reduction in YBOCS scores in the celecoxib treatment group at two weeks (P = 0.007) and at the eight week end-point (P = 0.037)
|
|
Minocycline
| | | | |
|
Levine et al. 1996 [264]
|
Case report
|
Minocycline (150 mg qd) started 20 years after disease onset
|
1 BPD
|
Marked decrease in depressive symptoms (HAM-D score went from 25 to 8) within one week following treatment, sustained at two weeks.
|
|
Levkovitz et al. 2009 [265]
|
RCT
|
Minocycline (200 mg qd) versus placebo
|
21 schizophrenia (early and acute-phase)
|
Significant improvement of negative symptoms and cognitive dysfunction in treatment group (P <0.01)
|
|
ClinicalTrials.gov NCT01433055 recruiting, estimated completion 7/15
|
RCT
|
Minocycline (100 mg bid) + clozapine versus placebo + clozapine
|
60 schizophrenia (refractory to ≥2 antipsychotics)
|
Primary outcome is the improvement in positive symptoms as measured by the four-item sub-factor of the Brief Psychiatric Rating Scale.
|
|
Miyaoka et al. 2007 [266]
|
Case series
|
Minocycline (150 mg qd) + stable antipsychotic regiment
|
2 schizophrenia
|
Complete resolution of positive and negative symptoms with minocycline, sustained for one to two years. Symptom exacerbation occurred one-week following minocycline discontinuation (in both cases). In one patient, the complete resolution of symptoms occurred at age 61, which was 41 years after disease onset.
|
|
Miyaoka et al. 2008 [267]
|
Open-label
|
Minocycline (150 mg tid)
|
22 schizophrenia
|
Significant improvement of positive and negative symptoms at four to eight weeks (P = 0.0001)
|
|
Rodriguez et al. 2010 [268]
|
Open-label
|
Minocycline (100 mg bid)
|
9 OCD
|
22% had a 40% to 46% YBOCS reduction at 12 weeks; the group as a whole did not have a significant change in YBOCS score.
|
